Among patients with chemotherapy-induced peripheral neuropathy, those treated with platinum-based agents, taxanes had highest prevalence<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 4, 2025 (HealthDay News) — The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral neuropathy (CIPN), according to a meta-analysis published online Jan. 28 in Regional Anesthesia & Pain Medicine<\/em>.<\/p>\n Ryan S. D’Souza, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a systematic review and meta-analysis to examine the prevalence of chronic painful neuropathy among patients diagnosed with CIPN. Estimates from each study were transformed using double arcsine transformation and pooled in a meta-analysis. Data were included from 77 studies from 28 countries, encompassing 10,962 patients with CIPN.<\/p>\n The researchers found that the pooled prevalence of those reporting chronic painful neuropathy among those diagnosed with CIPN was estimated at 41.22 percent. Across studies, there was considerable heterogeneity (I<\/em>2<\/sup> = 95.27 percent). Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful CIPN (40.44 and 38.35 percent, respectively); among primary cancers, the highest prevalence was reported by those with lung cancer (60.26 percent). Nonsignificant moderators of prevalence estimates included study design, human development index, and publication year.<\/p>\n “The wide variability in prevalence rates across different countries, continents, chemotherapy regimens, and primary cancer history underscores the need for tailored strategies to address this debilitating condition,” the authors write.<\/p>\n One author disclosed ties to the biopharmaceutical industry.<\/p>\n